Department of Urology, Daiyukai Daiichi Hospital, Aichi, Japan.
Department of Urology, Daiyukai Daiichi Hospital, Aichi, Japan.
Urology. 2014 Jun;83(6):1443.e9-15. doi: 10.1016/j.urology.2014.02.013. Epub 2014 Apr 13.
To examine urinary CD44v6 total ribonucleic acid (RNA) expression in patients with bladder cancer using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) and evaluate its potential as a novel marker of bladder cancer.
We used the bladder cancer cell line T24 and determined CD44v6 expression in cancer cells using in situ hybridization and immunohistochemistry. Subsequently, we obtained urine samples from 21 patients with bladder cancer and 25 patients without bladder cancer (controls). We extracted total RNA from the urine samples, measured CD44v6 total RNA expression in both groups using qRT-PCR, and compared the expression between groups. We also compared the sensitivity, specificity, and concordance rate between CD44v6 total RNA expression analysis by qRT-PCR and cytologic analysis, UroVysion fluorescent in situ hybridization, bladder tumor antigen identification, and nuclear matrix protein 22 measurements.
We observed increased CD44v6 expression in bladder cancer cells using in situ hybridization and immunohistochemistry. CD44v6 total RNA expression was significantly higher in the urine samples of patients with bladder cancer than in those of controls. We calculated the cutoff value from the receiver operating characteristic curve and obtained sensitivity and specificity values of 85.7% and 72.0%, respectively, for qRT-PCR analysis.
Our results suggest that CD44v6 total RNA levels in urine can serve as a potential noninvasive biomarker of bladder cancer.
采用实时定量逆转录聚合酶链反应（qRT-PCR）检测膀胱癌患者尿液 CD44v6 全长 RNA（RNA）表达，评估其作为膀胱癌新型标志物的潜力。
我们使用膀胱癌细胞系 T24，通过原位杂交和免疫组织化学检测癌细胞中 CD44v6 的表达。随后，我们收集了 21 例膀胱癌患者和 25 例非膀胱癌患者（对照组）的尿液样本。我们从尿液样本中提取总 RNA，采用 qRT-PCR 检测两组的 CD44v6 全长 RNA 表达，并比较两组之间的表达情况。我们还比较了 qRT-PCR 分析 CD44v6 全长 RNA 表达与细胞学分析、UroVysion 荧光原位杂交、膀胱肿瘤抗原鉴定和核基质蛋白 22 测量的敏感性、特异性和一致性。
我们通过原位杂交和免疫组织化学观察到膀胱癌细胞中 CD44v6 表达增加。膀胱癌患者尿液中 CD44v6 全长 RNA 表达明显高于对照组。我们从受试者工作特征曲线计算出临界值，并获得了 qRT-PCR 分析的敏感性和特异性值，分别为 85.7%和 72.0%。
我们的研究结果表明，尿液中 CD44v6 全长 RNA 水平可作为膀胱癌潜在的非侵入性生物标志物。
